WO2008154234A3 - Extended release formulation of nevirapine - Google Patents

Extended release formulation of nevirapine Download PDF

Info

Publication number
WO2008154234A3
WO2008154234A3 PCT/US2008/065705 US2008065705W WO2008154234A3 WO 2008154234 A3 WO2008154234 A3 WO 2008154234A3 US 2008065705 W US2008065705 W US 2008065705W WO 2008154234 A3 WO2008154234 A3 WO 2008154234A3
Authority
WO
WIPO (PCT)
Prior art keywords
nevirapine
extended release
release formulation
pharmaceutical composition
relates
Prior art date
Application number
PCT/US2008/065705
Other languages
French (fr)
Other versions
WO2008154234A9 (en
WO2008154234A2 (en
Inventor
Michael L. Cappola
Svetlana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008154234(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN2008800193577A priority Critical patent/CN101784263B/en
Priority to DK08756672.5T priority patent/DK2155169T3/en
Priority to ES08756672.5T priority patent/ES2574836T3/en
Priority to EA200900958A priority patent/EA018377B1/en
Priority to EP08756672.5A priority patent/EP2155169B1/en
Priority to NZ578664A priority patent/NZ578664A/en
Priority to AU2008262031A priority patent/AU2008262031B2/en
Priority to CA2687491A priority patent/CA2687491C/en
Priority to MX2009007764A priority patent/MX2009007764A/en
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim International Gmbh
Priority to UAA200908230A priority patent/UA97971C2/en
Priority to JP2009552940A priority patent/JP5417662B2/en
Priority to US12/523,226 priority patent/US8460704B2/en
Priority to BRPI0811732-2A2A priority patent/BRPI0811732A2/en
Publication of WO2008154234A2 publication Critical patent/WO2008154234A2/en
Priority to IL199924A priority patent/IL199924A0/en
Publication of WO2008154234A9 publication Critical patent/WO2008154234A9/en
Priority to TNP2009000510A priority patent/TN2009000510A1/en
Priority to MA32400A priority patent/MA31430B1/en
Publication of WO2008154234A3 publication Critical patent/WO2008154234A3/en
Priority to HK11100032.7A priority patent/HK1145806A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an extended release pharmaceutical composition comprising nevirapine.
PCT/US2008/065705 2007-06-08 2008-06-04 Extended release formulation of nevirapine WO2008154234A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
BRPI0811732-2A2A BRPI0811732A2 (en) 2007-06-08 2008-06-04 NEVIRAPINE PROLONGED RELEASE FORMULATION
JP2009552940A JP5417662B2 (en) 2007-06-08 2008-06-04 Nevirapine sustained release formulation
UAA200908230A UA97971C2 (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine
US12/523,226 US8460704B2 (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine
DK08756672.5T DK2155169T3 (en) 2007-06-08 2008-06-04 Formulation of nevirapine extended release
NZ578664A NZ578664A (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine
AU2008262031A AU2008262031B2 (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine
CA2687491A CA2687491C (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine
MX2009007764A MX2009007764A (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine.
CN2008800193577A CN101784263B (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine
ES08756672.5T ES2574836T3 (en) 2007-06-08 2008-06-04 Nevirapine prolonged release formulation
EP08756672.5A EP2155169B1 (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine
EA200900958A EA018377B1 (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine
IL199924A IL199924A0 (en) 2007-06-08 2009-07-16 Extended relase formulation of nevirapine
TNP2009000510A TN2009000510A1 (en) 2007-06-08 2009-12-04 Extended release formulation of nevirapine
MA32400A MA31430B1 (en) 2007-06-08 2009-12-07 PROLONGED RELEASE FORMULATION OF NEVIRAPINE
HK11100032.7A HK1145806A1 (en) 2007-06-08 2011-01-05 Extended release formulation of nevirapine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08
US60/942,765 2007-06-08

Publications (3)

Publication Number Publication Date
WO2008154234A2 WO2008154234A2 (en) 2008-12-18
WO2008154234A9 WO2008154234A9 (en) 2009-11-26
WO2008154234A3 true WO2008154234A3 (en) 2010-01-21

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/065705 WO2008154234A2 (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine

Country Status (29)

Country Link
US (1) US8460704B2 (en)
EP (1) EP2155169B1 (en)
JP (1) JP5417662B2 (en)
KR (1) KR101017862B1 (en)
CN (1) CN101784263B (en)
AR (1) AR066924A1 (en)
AU (1) AU2008262031B2 (en)
BR (1) BRPI0811732A2 (en)
CA (1) CA2687491C (en)
CL (1) CL2008001678A1 (en)
CO (1) CO6150128A2 (en)
DK (1) DK2155169T3 (en)
EA (1) EA018377B1 (en)
EC (1) ECSP099561A (en)
ES (1) ES2574836T3 (en)
HK (1) HK1145806A1 (en)
HU (1) HUE028598T2 (en)
IL (1) IL199924A0 (en)
MA (1) MA31430B1 (en)
MX (1) MX2009007764A (en)
NZ (1) NZ578664A (en)
PE (2) PE20131035A1 (en)
PL (1) PL2155169T3 (en)
TN (1) TN2009000510A1 (en)
TW (1) TWI419716B (en)
UA (1) UA97971C2 (en)
UY (1) UY31128A1 (en)
WO (1) WO2008154234A2 (en)
ZA (1) ZA200904939B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
UA97971C2 (en) 2007-06-08 2012-04-10 Берингер Ингельхайм Интернациональ Гмбх Extended release formulation of nevirapine
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
US20140193491A1 (en) 2011-05-30 2014-07-10 Cipla Limited Pharmaceutical antiretroviral composition
US20130084277A1 (en) * 2011-08-24 2013-04-04 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
CN104203244A (en) * 2012-03-05 2014-12-10 希普拉有限公司 Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
CN104523630B (en) * 2015-01-22 2017-08-25 山东新时代药业有限公司 A kind of NVP tablet
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035419A2 (en) * 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US20020006439A1 (en) * 1997-09-09 2002-01-17 Robert R. Skluzacek Dosage form comprising means for changing drug delivery shape
US20020068085A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antiviral product, use and formulation thereof
WO2007047371A2 (en) * 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
PT1035834E (en) 1997-12-05 2002-09-30 Alza Corp OSMOTIC DOSE FORMAT COMPREHENDING FIRST AND SECOND COATINGS
EA005291B1 (en) * 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Pregelatinized starch in a controlled release formulation
PT1225874E (en) * 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv ANTIVIRAL COMPOSITIONS.
AU2084801A (en) 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
CA2529852A1 (en) 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
ES2286716T3 (en) 2003-10-01 2007-12-01 Lupin Limited PHARMACEUTICAL COMPOSITION OF CONTROLLED LIBERATION AND PROCESS TO PREPARE THE SAME.
DK1696822T3 (en) 2003-11-13 2010-05-17 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible housing
PL1632232T6 (en) * 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
AU2006263338A1 (en) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
US9198862B2 (en) * 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
FR2891459B1 (en) 2005-09-30 2007-12-28 Flamel Technologies Sa MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME
UA97971C2 (en) 2007-06-08 2012-04-10 Берингер Ингельхайм Интернациональ Гмбх Extended release formulation of nevirapine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006439A1 (en) * 1997-09-09 2002-01-17 Robert R. Skluzacek Dosage form comprising means for changing drug delivery shape
WO2000035419A2 (en) * 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US20020068085A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antiviral product, use and formulation thereof
WO2007047371A2 (en) * 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination

Also Published As

Publication number Publication date
CA2687491C (en) 2011-09-20
AU2008262031A1 (en) 2008-12-18
AU2008262031B2 (en) 2011-08-25
CN101784263A (en) 2010-07-21
CL2008001678A1 (en) 2009-09-11
BRPI0811732A2 (en) 2014-11-18
MA31430B1 (en) 2010-06-01
EA200900958A1 (en) 2010-04-30
HK1145806A1 (en) 2011-05-06
EP2155169B1 (en) 2016-03-23
PL2155169T3 (en) 2016-09-30
CN101784263B (en) 2012-11-07
TN2009000510A1 (en) 2011-03-31
KR20100020447A (en) 2010-02-22
TW200916127A (en) 2009-04-16
DK2155169T3 (en) 2016-06-13
PE20090371A1 (en) 2009-04-24
MX2009007764A (en) 2009-09-10
WO2008154234A9 (en) 2009-11-26
NZ578664A (en) 2011-11-25
WO2008154234A2 (en) 2008-12-18
EP2155169A2 (en) 2010-02-24
EA018377B1 (en) 2013-07-30
ECSP099561A (en) 2009-09-29
CO6150128A2 (en) 2010-04-20
CA2687491A1 (en) 2008-12-18
UY31128A1 (en) 2009-01-30
JP5417662B2 (en) 2014-02-19
HUE028598T2 (en) 2016-12-28
PE20131035A1 (en) 2013-10-01
AR066924A1 (en) 2009-09-23
ES2574836T3 (en) 2016-06-22
US8460704B2 (en) 2013-06-11
UA97971C2 (en) 2012-04-10
TWI419716B (en) 2013-12-21
JP2010520891A (en) 2010-06-17
ZA200904939B (en) 2010-04-28
US20100278918A1 (en) 2010-11-04
IL199924A0 (en) 2010-04-15
KR101017862B1 (en) 2011-03-04

Similar Documents

Publication Publication Date Title
HUS1800043I1 (en) Pharmaceutical formulation 514
WO2008154234A3 (en) Extended release formulation of nevirapine
EP2130552A4 (en) Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
IL204844A (en) Quinolone analogs, pharmaceutical compositions comprising the same and uses thereof
ME02478B (en) Solid pharmaceutical formulations comprising bibw 2992
IL213583A0 (en) Solid compositions containing the ingredient rasagiline
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
WO2011077043A3 (en) Phenol derivatives and pharmaceutical or cosmetic use thereof
WO2009156462A3 (en) Organic compounds
WO2007109604A3 (en) Pharmaceutical compositions
WO2007109605A3 (en) Pharmaceutical compositions
EP2078731A4 (en) Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
IL206808A (en) Indolyl-pyridone derivatives, pharmaceutical compositions comprising the same and uses thereof
WO2010021607A3 (en) Pharmaceutical formulation
EP2285357B8 (en) Pharmaceutical compositions comprising brivaracetam
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
EP2241569A4 (en) Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses
EP2644614A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
WO2009094457A3 (en) Substituted benzhydrylethers
WO2008073863A3 (en) Preparation and utility of substituted allylamines
WO2009035959A3 (en) Radiofluorination methods
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
IL212171A (en) 1-phenylpyrrole compounds, pharmaceutical compositions comprising them and their uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880019357.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08756672

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008756672

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 199924

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009071101

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 4724/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 09075419

Country of ref document: CO

Ref document number: MX/A/2009/007764

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12009501433

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 578664

Country of ref document: NZ

Ref document number: 2008262031

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200900958

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020097016610

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008262031

Country of ref document: AU

Date of ref document: 20080604

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009552940

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12523226

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2687491

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2010000003

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: A200908230

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0811732

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091127